Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
VERU 
Veru Inc (VERU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: VERU (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $19.75
1 Year Target Price $19.75
| 2 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -57.97% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 37.88M USD | Price to earnings Ratio 0.4 | 1Y Target Price 19.75 |
Price to earnings Ratio 0.4 | 1Y Target Price 19.75 | ||
Volume (30-day avg) 5 | Beta -1.01 | 52 Weeks Range 2.11 - 14.20 | Updated Date 12/3/2025 |
52 Weeks Range 2.11 - 14.20 | Updated Date 12/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 5.9 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-12-01 | When - | Estimate -0.0567 | Actual - |
Profitability
Profit Margin -193.71% | Operating Margin (TTM) -227.14% |
Management Effectiveness
Return on Assets (TTM) -52.13% | Return on Equity (TTM) -106.02% |
Valuation
Trailing PE 0.4 | Forward PE 117.65 | Enterprise Value 26764922 | Price to Sales(TTM) 2.24 |
Enterprise Value 26764922 | Price to Sales(TTM) 2.24 | ||
Enterprise Value to Revenue 1.58 | Enterprise Value to EBITDA -3.23 | Shares Outstanding 16050392 | Shares Floating 13217291 |
Shares Outstanding 16050392 | Shares Floating 13217291 | ||
Percent Insiders 14.19 | Percent Institutions 24.3 |
Upturn AI SWOT
Veru Inc
Company Overview
History and Background
Veru Inc., formerly known as Female Health Company, was founded in 1999. Initially focused on sexual health products, the company has evolved to focus on developing medicines for oncology and infectious diseases. A significant milestone was the development and commercialization of the FC2 female condom. The company has shifted its focus to cancer and viral disease drug development.
Core Business Areas
- Oncology: Development and commercialization of therapies for prostate cancer and other cancers.
- Infectious Diseases: Development of antiviral therapies.
Leadership and Structure
Mitchell S. Steiner, M.D. serves as Chairman, President, and Chief Executive Officer. The company has a board of directors and operates with a functional organizational structure, including R&D, commercial, and administrative departments.
Top Products and Market Share
Key Offerings
- Sabizabulin: An oral drug being developed for the treatment of severe COVID-19 and prostate cancer. The prostate cancer market is highly competitive with established players like Pfizer (PFE) and Johnson & Johnson (JNJ). COVID-19 market is similarly competitive with a range of vaccines and therapeutics from companies such as Pfizer (PFE), Merck (MRK) and Gilead (GILD). Veru sought EUA but the FDA declined to issue EUA due to limitations in the study data.
- FC2 Female Condom: A female condom distributed in both the public and commercial sectors. Market share data is not readily available. Competitors in the sexual health market include Church & Dwight (CHD) with Trojan condoms.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, strict regulatory requirements, and intense competition. The oncology market is experiencing rapid growth, driven by aging populations and advancements in cancer treatment. The antiviral market fluctuates based on emerging infectious diseases.
Positioning
Veru Inc. is a small-cap pharmaceutical company focused on niche areas within oncology and infectious diseases. Its competitive advantage lies in its proprietary drug candidates and its ability to target unmet medical needs.
Total Addressable Market (TAM)
The global oncology market is projected to reach hundreds of billions of dollars. The prostate cancer TAM is significant and growing. Veru is positioned to capture a portion of this market with Sabizabulin. The antiviral market, while volatile, represents another significant TAM, where Veru has positioned Sabizabulin and other drug candidates in this space.
Upturn SWOT Analysis
Strengths
- Proprietary drug candidates
- Experienced management team
- Focus on unmet medical needs
- FC2 business provides revenue
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- High regulatory risk
- Small market capitalization
Opportunities
- Successful clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Acquisition or licensing of new drug candidates
Threats
- Failure of clinical trials
- Regulatory setbacks
- Competition from larger pharmaceutical companies
- Patent expiration
- Inability to raise capital
Competitors and Market Share
Key Competitors
- PFE
- MRK
- JNJ
- GILD
- CHD
Competitive Landscape
Veru faces intense competition from larger pharmaceutical companies with greater financial and marketing resources. Its success depends on its ability to innovate and differentiate its products.
Growth Trajectory and Initiatives
Historical Growth: Veru's historical growth has been driven by the commercialization of FC2 and its pipeline development. Revenue is volatile year to year based on sales.
Future Projections: Future growth depends on the successful development and commercialization of Sabizabulin and other drug candidates. Analyst estimates vary widely based on clinical trial outcomes. The estimates change and vary.
Recent Initiatives: Recent initiatives include advancing Sabizabulin through clinical trials and seeking regulatory approval for COVID-19 and prostate cancer.
Summary
Veru Inc. is a small-cap pharmaceutical company with potential in oncology and infectious diseases, but faces challenges due to limited resources and dependence on clinical trial results. While its focus on unmet needs presents opportunities, competition from larger players and regulatory hurdles pose significant risks. The FC2 business provides a revenue stream, but the company's future hinges on the successful development and commercialization of its drug pipeline. Recent initiatives with Sabizabulin are crucial for its growth trajectory, although the FDA declined EUA due to limitations in the study data.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Press releases
- Company website
- Third-party financial data providers
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It should not be considered financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market Share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Veru Inc
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 1990-07-19 | Chairman, President & CEO Dr. Mitchell S. Steiner F.A.C.S., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 210 | Website https://verupharma.com |
Full time employees 210 | Website https://verupharma.com | ||
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.